Gland Pharma has announced its financial results for the second quarter of FY27, showcasing robust performance. Revenue from operations increased by 23% YoY to ₹18,336 million. Profit After Tax (PAT) surged by 58% YoY to ₹2,908 million. The company also highlighted significant growth in EBITDA and PBT, with Adjusted EBITDA up 50% YoY.
Gland Pharma Announces Strong Q2 FY27 Financials
Gland Pharma Limited has released its financial results for the second quarter ending September 30, 2026 (Q2 FY27), demonstrating considerable year-on-year growth across key financial parameters.
Consolidated Profit and Loss Highlights
The company reported a significant increase in its Revenue from operations, which grew by 23% YoY to ₹18,336 million for Q2 FY27, compared to ₹14,869 million in Q2 FY26. Total Income also saw a healthy rise of 21% YoY to ₹19,026 million.
Gross Profit for the quarter stood at ₹11,638 million, an increase of 25% YoY, maintaining a Gross Profit Margin of 63%. EBITDA recorded a substantial jump of 53% YoY to ₹4,804 million, with an EBITDA margin of 26%. Adjusted EBITDA further improved by 50% YoY to ₹5,030 million, with an Adjusted EBITDA margin of 27%.
Profit Before Tax (PBT) witnessed a strong growth of 52% YoY, reaching ₹4,309 million. The most notable highlight is the Profit After Tax (PAT), which surged by an impressive 58% YoY to ₹2,908 million, up from ₹1,837 million in the prior year’s corresponding quarter. PAT margin for the quarter was 16%.
Six-Month Performance
For the six months ended September 30, 2026 (6M FY27), Revenue from operations increased by 21% YoY to ₹36,339 million. Total Income grew by 20% YoY to ₹37,641 million. Gross Profit rose by 22% YoY to ₹23,397 million.
EBITDA for the six-month period was ₹9,734 million, up by 43% YoY. Adjusted EBITDA also increased by 43% YoY to ₹10,132 million. PBT for 6M FY27 stood at ₹8,659 million (up 45% YoY). PAT for the six months grew by 52% YoY to ₹6,077 million.
Business and Geographical Updates
The presentation also detailed business-wise revenue break-ups, with CDMO and Critical Injectables segments both showing year-on-year growth. CDMO revenue grew by 31% YoY in Q2 FY27, while Critical Injectables saw an 18% YoY increase. Geographically, the US market remains a significant contributor, with the company reporting new product launches and strong growth drivers in both CDMO and Critical Injectables segments.
The Europe market also demonstrated growth, with Total Revenue up 30% YoY in Q2 FY27. Other core markets and the Rest of the World showed mixed performance, with specific business updates provided for each region.
R&D expenses for Q2 FY27 were ₹1,077 million, representing 6% of consolidated revenue, an increase from ₹817 million in Q2 FY26. The company also highlighted new product launches, filings and approvals, and progress in its complex pipeline and partnerships.
Source: BSE
